150 related articles for article (PubMed ID: 35538302)
1. Involvement of DA D3 Receptors in Structural Neuroplasticity of Selected Limbic Brain Circuits: Possible Role in Treatment-Resistant Depression.
Merlo Pich E; Cavalleri L; Toma C; Collo G
Curr Top Behav Neurosci; 2023; 60():73-87. PubMed ID: 35538302
[TBL] [Abstract][Full Text] [Related]
2. Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling.
Cavalleri L; Merlo Pich E; Millan MJ; Chiamulera C; Kunath T; Spano PF; Collo G
Mol Psychiatry; 2018 Apr; 23(4):812-823. PubMed ID: 29158584
[TBL] [Abstract][Full Text] [Related]
3. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling.
Collo G; Cavalleri L; Bono F; Mora C; Fedele S; Invernizzi RW; Gennarelli M; Piovani G; Kunath T; Millan MJ; Merlo Pich E; Spano P
Neural Plast; 2018; 2018():4196961. PubMed ID: 29531524
[TBL] [Abstract][Full Text] [Related]
4. Structural Plasticity Induced by Ketamine in Human Dopaminergic Neurons as Mechanism Relevant for Treatment-Resistant Depression.
Collo G; Cavalleri L; Merlo Pich E
Chronic Stress (Thousand Oaks); 2019; 3():2470547019842545. PubMed ID: 32440593
[TBL] [Abstract][Full Text] [Related]
5. Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling.
Collo G; Bono F; Cavalleri L; Plebani L; Mitola S; Merlo Pich E; Millan MJ; Zoli M; Maskos U; Spano P; Missale C
Mol Pharmacol; 2013 Jun; 83(6):1176-89. PubMed ID: 23543412
[TBL] [Abstract][Full Text] [Related]
6. Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons.
Bono F; Savoia P; Guglielmi A; Gennarelli M; Piovani G; Sigala S; Leo D; Espinoza S; Gainetdinov RR; Devoto P; Spano P; Missale C; Fiorentini C
Mol Neurobiol; 2018 Feb; 55(2):1054-1067. PubMed ID: 28092083
[TBL] [Abstract][Full Text] [Related]
7. Ketamine effects on mammalian target of rapamycin signaling in the mouse limbic system depend on functional dopamine D3 receptors.
Chiamulera C; di Chio M; Cavalleri L; Venniro M; Padovani L; Collo G
Neuroreport; 2018 May; 29(8):615-620. PubMed ID: 29570499
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
Collo G; Zanetti S; Missale C; Spano P
Eur J Neurosci; 2008 Oct; 28(7):1231-40. PubMed ID: 18973551
[TBL] [Abstract][Full Text] [Related]
9. Pre-synaptic dopamine D(3) receptor mediates cocaine-induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways.
Collo G; Bono F; Cavalleri L; Plebani L; Merlo Pich E; Millan MJ; Spano PF; Missale C
J Neurochem; 2012 Mar; 120(5):765-78. PubMed ID: 22145570
[TBL] [Abstract][Full Text] [Related]
10. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex.
Zhou W; Wang N; Yang C; Li XM; Zhou ZQ; Yang JJ
Eur Psychiatry; 2014 Sep; 29(7):419-23. PubMed ID: 24321772
[TBL] [Abstract][Full Text] [Related]
11. The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease.
Razgado-Hernandez LF; Espadas-Alvarez AJ; Reyna-Velazquez P; Sierra-Sanchez A; Anaya-Martinez V; Jimenez-Estrada I; Bannon MJ; Martinez-Fong D; Aceves-Ruiz J
PLoS One; 2015; 10(2):e0117391. PubMed ID: 25693197
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.
Du F; Li R; Huang Y; Li X; Le W
Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585
[TBL] [Abstract][Full Text] [Related]
13. Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain.
Bustos G; Abarca J; Campusano J; Bustos V; Noriega V; Aliaga E
Brain Res Brain Res Rev; 2004 Dec; 47(1-3):126-44. PubMed ID: 15572168
[TBL] [Abstract][Full Text] [Related]
14. TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats.
Hara H; Suzuki A; Kunugi A; Tajima Y; Yamada R; Kimura H
Pharmacol Biochem Behav; 2021 Dec; 211():173289. PubMed ID: 34655652
[TBL] [Abstract][Full Text] [Related]
15. Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.
Licznerski P; Duman RS
Neuroscience; 2013 Oct; 251():33-50. PubMed ID: 23036622
[TBL] [Abstract][Full Text] [Related]
16. Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc.
Szewczyk B; Pochwat B; Rafało A; Palucha-Poniewiera A; Domin H; Nowak G
Neuropharmacology; 2015 Dec; 99():517-26. PubMed ID: 26297535
[TBL] [Abstract][Full Text] [Related]
17. Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway.
Mutti V; Bono F; Tomasoni Z; Bontempi L; Guglielmi A; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
Mol Neurobiol; 2022 Apr; 59(4):2129-2149. PubMed ID: 35044626
[TBL] [Abstract][Full Text] [Related]
18. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.
Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM
J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs.
Pich EM; Collo G
Eur Neuropsychopharmacol; 2015 Sep; 25(9):1437-47. PubMed ID: 26298833
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression.
Leggio GM; Salomone S; Bucolo C; Platania C; Micale V; Caraci F; Drago F
Eur J Pharmacol; 2013 Nov; 719(1-3):25-33. PubMed ID: 23872400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
